1[1]Canal N,Imbimbo B.For the eptastigmine study group.Clinical trial and therapeutionship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimers disease[J].Clin Phamcol Ther,1996,60:218.
2[2]Trabace L, Coluccia A,Gaetadi S,et al.In vivo neurochemical effect of the acetycholineterase inhibitor ENA-713 In rat hippocampus[J].Brain Res,2000,865(2),268.
3[3]Trabace,Luigia,Cassanso,Tomnaso,et al.Biochemical and neurobehavioral profile of CHF2819.a novel,orally active AchEI for AD[J].J Pharmacol Exp Ther,2000,294(1),187.
4[4]Camp,Pelayo,Cusack,et al.Huprine X is a novel high-affinity inhibitor of AchE that is of interest for treatment of AD[J].Mol Pharmacol,2000,57(2),409.
5[5]Sugimoto,Hachiro,yamanishi et al.Donepezil hydro chloride (9E2020)and other AchEIs Curr[J].Med Chem,2000,(3):303.
6[6]Ishihara,Yuji,Goto,et al.Central selective AchEI with neurotrophic activity:structure relationships of TAK-147 and related compounds[J].Curr Med Chen,2000,7(3):341.
7[7]Villabos A,Butler TN,Chapin DS,et al.Apotent and centrally selective inhibitor of acetyicholinesterase with improved marginof safety[J].J Med,1995,38:2802.
8[8]Sramek,john J,Hourani,et al .Nxx-066 in patient with AD:abridging study[J].Life sci,1999,64(14):1215.
9[9]Zeng FanXing,Jiang Hualiang,Zhai,et al.Synthesis and AchEI activity of Huperzine A-E2020 Combined[J].Bioorg Med Chen iett,1999,9(23):3279.
